News
Each of these exchange-traded funds offers a different way to make a defensive pivot.
Via The Motley Fool · September 24, 2026
With a trailing-10-year total return of 572%, this popular exchange-traded fund has been a fantastic portfolio addition.
Via The Motley Fool · September 24, 2026
With enough time and discipline, even small monthly investments can turn into $1 million or more over time.
Via The Motley Fool · September 24, 2026
Look to sectors that actually benefit from higher interest rates.
Via The Motley Fool · September 24, 2026
ARKX holds 60% industrials with space-tech leaders like SpaceX, while JETS concentrates on airlines.
Via The Motley Fool · September 24, 2026
Real-world asset tokenization is moving beyond the idea of simply putting ownership records on a blockchain. The more important question begins after the t
Via Talk Markets · September 24, 2026
Vanguard is more diversified with a higher dividend yield, while State Street's concentrated 30-stock portfolio charges a lower expense ratio.
Via The Motley Fool · September 23, 2026
Anheuser-Busch InBev SA/NV (NYSE:BUD) outlined a new medium-term target for 5% to 9% average annual EBIT growth as the brewer shifts its primary performance measure from EBITDA to EBIT, citing improved balance-sheet strength, capital efficiency and an increased focus on organic growth.
Speaking at
Via MarketBeat · September 23, 2026
Everpure (NYSE:P) outlined an expanded technology strategy centered on what executives called “data primacy,” arguing that artificial intelligence is pushing enterprises to organize IT architectures around data rather than individual applications.
At its financial analyst meeting in Santa Clara, Ch
Via MarketBeat · September 23, 2026
Everpure (NYSE:P) outlined a strategy centered on expanding its enterprise storage business while pursuing new opportunities in AI infrastructure, data software and hyperscale deployments, with executives projecting accelerated growth and higher profitability through fiscal 2028.
At the company’s i
Via MarketBeat · September 23, 2026
XLV's broader diversification and lower fees appeal to cost-conscious investors, while PJP's concentrated pharma bet has outperformed over the past year.
Via The Motley Fool · September 23, 2026
SCHD also has one of the best track records of growing over time too.
Via The Motley Fool · September 23, 2026
VT holds more than 10,000 stocks across global markets while VWO focuses on more than 6,000 emerging-market holdings. VT delivered stronger five-year returns despite a lower dividend yield.
Via The Motley Fool · September 23, 2026
State Street offers a higher yield and lower costs, but Vanguard's broader portfolio of 103 holdings delivered stronger five-year returns.
Via The Motley Fool · September 23, 2026
The S&P 500's current concentration has its benefits and risks.
Via The Motley Fool · September 23, 2026
Vanguard's S&P 500 ETF is still my top recommendation for passive investors.
Via The Motley Fool · September 23, 2026
VDE's traditional oil holdings delivered 46.8% returns over one year, while ICLN's renewable focus saw deeper volatility and a 57.2% maximum drawdown.
Via The Motley Fool · September 23, 2026
Colgate-Palmolive's removal from the index doesn't indicate its business is crumbling.
Via The Motley Fool · September 23, 2026
Vanguard FTSE Canada All Cap Index ETF (TSX:VCN) could be a long-term winner as Canada becomes more attractive following the latest investment summit.
Via The Motley Fool · September 23, 2026
The S&P 500 has been perhaps the greatest wealth generation machine of the past several decades.
Via The Motley Fool · September 23, 2026
The State Street SPDR S&P Dividend ETF could be the ideal dividend fund if the U.S. economy cools.
Via The Motley Fool · September 23, 2026
Invesco's QQQ Trust is still one of the easiest ways to beat the market.
Via The Motley Fool · September 23, 2026
AGF Management (TSE:AGF.B) reported third-quarter 2026 adjusted diluted earnings per share of CAD 0.49, adjusted EBITDA of CAD 49 million and free cash flow of CAD 39 million, as growth in assets under management and retail sales momentum supported results.
Chief Executive Officer Judy Goldring sai
Via MarketBeat · September 23, 2026
Regeneron Pharmaceuticals (NASDAQ:REGN) executives highlighted continued growth across key marketed products, a broad late-stage pipeline and an ongoing focus on science-driven business development during a discussion with Bernstein analyst Jeffrey Walch.
Chris Fenimore, Regeneron’s executive vice
Via MarketBeat · September 23, 2026
There are not many ETFs that can match this ETF on performance.
Via The Motley Fool · September 23, 2026